Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Phase 3 Trial of Ibrutinib Plus Rituximab in Previously Treated Waldenstrom's Macroglobulinemia
2013-005478-22Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Waldenström macroglobulinemia (WM) comparing Ibrutinib + rituximab with Placebo + rituximab (2 arms). Primary endpoint: Progression-free survival by independent review committee. Started Apr 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2013-005478-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005478-22.